{"title":"Association between lipoprotein(a) and coronary heart disease risk in type 2 diabetes mellitus and evaluation of statin treatment effects.","authors":"Li Li, Liwu Xu","doi":"10.1590/1806-9282.20240870","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to investigate the association between lipoprotein(a) and coronary heart disease risk in type 2 diabetes mellitus patients and evaluate the effectiveness of statin therapy.</p><p><strong>Methods: </strong>This retrospective analysis included 120 patients diagnosed with type 2 diabetes mellitus. Of these, 90 patients diagnosed with coronary heart disease via coronary angiography received rosuvastatin treatment for over 6 months. The remaining 30 patients exhibited no coronary heart disease or other diabetic macrovascular complications and had not received any lipid-lowering treatment. Patients with type 2 diabetes mellitus and coronary heart disease were categorized into two groups based on the severity of coronary lesions. Baseline characteristics and blood lipid data were compared among groups. Logistic regression analysis was employed to investigate the association between lipoprotein(a) and coronary heart disease risk in type 2 diabetes mellitus patients. Receiver operating characteristic curves were utilized to evaluate the diagnostic value of lipoprotein(a) for coronary heart disease.</p><p><strong>Results: </strong>Compared with the control group, lipoprotein(a) levers were higher in both the mild and severe groups. Logistic regression analysis demonstrated that lipoprotein(a) is independently associated with the risk of coronary heart disease in type 2 diabetes mellitus patients. The area under the receiver operating characteristic curve for lipoprotein(a) was 0.729. When lipoprotein(a) was 97.5 mg/L, the diagnosis of coronary heart disease had high sensitivity and specificity. After statin therapy, high-density lipoprotein cholesterol and apolipoprotein A levels increased, while other lipid parameters decreased. However, the lipoprotein(a) level decrease was not statistically significant.</p><p><strong>Conclusion: </strong>Lipoprotein(a) is an independent risk factor for coronary heart disease in type 2 diabetes mellitus patients. Lipid-lowering therapy with statins alone cannot reduce lipoprotein(a) levels.</p>","PeriodicalId":94194,"journal":{"name":"Revista da Associacao Medica Brasileira (1992)","volume":"71 1","pages":"e20240870"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918843/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista da Associacao Medica Brasileira (1992)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/1806-9282.20240870","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The aim of this study was to investigate the association between lipoprotein(a) and coronary heart disease risk in type 2 diabetes mellitus patients and evaluate the effectiveness of statin therapy.
Methods: This retrospective analysis included 120 patients diagnosed with type 2 diabetes mellitus. Of these, 90 patients diagnosed with coronary heart disease via coronary angiography received rosuvastatin treatment for over 6 months. The remaining 30 patients exhibited no coronary heart disease or other diabetic macrovascular complications and had not received any lipid-lowering treatment. Patients with type 2 diabetes mellitus and coronary heart disease were categorized into two groups based on the severity of coronary lesions. Baseline characteristics and blood lipid data were compared among groups. Logistic regression analysis was employed to investigate the association between lipoprotein(a) and coronary heart disease risk in type 2 diabetes mellitus patients. Receiver operating characteristic curves were utilized to evaluate the diagnostic value of lipoprotein(a) for coronary heart disease.
Results: Compared with the control group, lipoprotein(a) levers were higher in both the mild and severe groups. Logistic regression analysis demonstrated that lipoprotein(a) is independently associated with the risk of coronary heart disease in type 2 diabetes mellitus patients. The area under the receiver operating characteristic curve for lipoprotein(a) was 0.729. When lipoprotein(a) was 97.5 mg/L, the diagnosis of coronary heart disease had high sensitivity and specificity. After statin therapy, high-density lipoprotein cholesterol and apolipoprotein A levels increased, while other lipid parameters decreased. However, the lipoprotein(a) level decrease was not statistically significant.
Conclusion: Lipoprotein(a) is an independent risk factor for coronary heart disease in type 2 diabetes mellitus patients. Lipid-lowering therapy with statins alone cannot reduce lipoprotein(a) levels.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
